

Raquel De Souza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10674882/publications.pdf>

Version: 2024-02-01

23
papers

848
citations

516710

16
h-index

713466

21
g-index

23
all docs

23
docs citations

23
times ranked

1647
citing authors

#	ARTICLE	IF	CITATIONS
1	Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 472-485.	4.6	24
2	Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. <i>PLoS ONE</i> , 2018, 13, e0196892.	2.5	5
3	Companion Diagnostic ⁶⁴ Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. <i>Theranostics</i> , 2018, 8, 2300-2312.	10.0	47
4	Significant Radiation Enhancement Effects by Gold Nanoparticles in Combination with Cisplatin in Triple Negative Breast Cancer Cells and Tumor Xenografts. <i>Radiation Research</i> , 2017, 187, 147-160.	1.5	44
5	Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2060-2071.	4.1	51
6	Development of a liposome formulation for improved biodistribution and tumor accumulation of pentamidine for oncology applications. <i>International Journal of Pharmaceutics</i> , 2015, 488, 154-164.	5.2	16
7	Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents. <i>Journal of Controlled Release</i> , 2015, 219, 313-330.	9.9	10
8	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. <i>Journal of Controlled Release</i> , 2015, 219, 295-312.	9.9	11
9	Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease. <i>Molecular Pharmaceutics</i> , 2015, 12, 3973-3985.	4.6	24
10	A multimodal nano agent for image-guided cancer surgery. <i>Biomaterials</i> , 2015, 67, 160-168.	11.4	45
11	The impact of sustained and intermittent docetaxel chemotherapy regimens on cognition and neural morphology in healthy mice. <i>Psychopharmacology</i> , 2014, 231, 841-852.	3.1	35
12	Nanotechnology for Multimodality Imaging: Applications in Disease Detection and Treatment Guidance. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 145-193.	0.1	0
13	Continuous Intraperitoneal Carboplatin Delivery for the Treatment of Late-Stage Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2013, 10, 3315-3322.	4.6	8
14	Abstract C293: Irinotecan sucrosfate liposome injection, MM-398, demonstrates superior activity and control of hypoxia as measured through longitudinal imaging using [¹⁸ F]FAZA PET compared to free irinotecan in a colon adenocarcinoma xenograft model.. , 2013, , .		2
15	An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels. <i>Journal of Controlled Release</i> , 2012, 158, 379-385.	9.9	29
16	Combination Drug Delivery Strategy for the Treatment of Multidrug Resistant Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2011, 8, 260-269.	4.6	46
17	Docetaxel Distribution Following Intraperitoneal Administration in Mice. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2011, 14, 90.	2.1	12
18	Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1289-1299.	4.1	68

#	ARTICLE	IF	CITATIONS
19	Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1820-1830.	4.1	36
20	Polymeric drug delivery systems for localized cancer chemotherapy. <i>Drug Delivery</i> , 2010, 17, 365-375.	5.7	158
21	Chitosan-phospholipid blend for sustained and localized delivery of docetaxel to the peritoneal cavity. <i>International Journal of Pharmaceutics</i> , 2009, 377, 76-84.	5.2	32
22	Biocompatibility of injectable chitosan-phospholipid implant systems. <i>Biomaterials</i> , 2009, 30, 3818-3824.	11.4	82
23	Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 907-914.	2.3	63